Combined thrombectomy and intracoronary administration of glycoprotein IIb/IIIa inhibitors improves myocardial reperfusion in patients undergoing primary percutaneous coronary intervention: a meta-analysis

被引:6
|
作者
Niu, Xiao-Wei [1 ]
Zhang, Jing-Jing [2 ]
Bai, Ming [3 ]
Peng, Yu [3 ]
Zhang, Zheng [3 ]
机构
[1] Lanzhou Univ, Clin Med Sch 1, Lanzhou, Gansu, Peoples R China
[2] Baiyin Second Peoples Hosp, Baiyin, Peoples R China
[3] Lanzhou Univ, Dept Cardiol, Hosp 1, 1 Donggang West Rd, Lanzhou 730000, Gansu, Peoples R China
关键词
Glycoprotein IIb/IIIa inhibitors; Meta-analysis; Myocardial reperfusion; Thrombectomy; Percutaneous coronary intervention; MANUAL THROMBUS ASPIRATION; PRIMARY ANGIOPLASTY; COMBINATION TREATMENT; INFARCTION; ABCIXIMAB; TIROFIBAN; PERFUSION; IMPACT; EPTIFIBATIDE; MORTALITY;
D O I
10.11909/j.issn.1671-5411.2017.10.002
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Suboptimal myocardial reperfusion is common in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Furthermore, it results in increased infarct size and mortality rates. We performed a meta-analysis to evaluate the role of aspiration thrombectomy (AT) combined with intracoronary administration of glycoprotein IIb/IIIa inhibitors (GPI) in the improvement of myocardial reperfusion and clinical outcomes. Methods PubMed, Embase, Web of Science, and CENTRAL databases were searched for randomized controlled trials (RCTs) investigating combined AT and intracoronary GPI treatment versus AT alone. Outcomes of interest were thrombolysis in myocardial infarction myocardial perfusion grade (TMPG), infarct size (IS) assessed by cardiac magnetic resonance imaging, left ventricular ejection fraction (LVEF), major adverse cardiac events (MACE) at short-term (<= 1 month) and long-term (6. 12 months) follow-up, and bleeding complications during the hospital stay. Results Eight trials involving 923 patients were included. Compared with AT alone, combined AT and intracoronary GPI significantly increased TMPG 3 flow (RR: 1.15, 95% CI: 1.04 to 1.26), reduced IS [mean difference (MD): -3.46, 95% CI: -5.18 to -1.73], and improved LVEF (MD: 1.44, 95% CI: 0.54 to 2.33). Furthermore, GPI use decreased the risk of MACE at long-term follow-up (RR: 0.60, 95% CI: 0.37 to 0.98). There was no significant difference between the two groups in the incidence of minor and major bleeding complications. Conclusions Our findings showed that compared with AT alone, combined AT and intracoronary GPI treatment resulted in improved myocardial reperfusion, better cardiac function, and MACE-free survival benefits at the long-term follow-up for patients with STEMI undergoing PPCI.
引用
收藏
页码:614 / 623
页数:10
相关论文
共 50 条
  • [1] Combined thrombectomy and intracoronary administration of glycoprotein Ⅱb/Ⅲa inhibitors improves myocardial reperfusion in patients undergoing primary percutaneous coronary intervention:a meta-analysis
    XiaoWei NIU
    JingJing ZHANG
    Ming BAI
    Yu PENG
    Zheng ZHANG
    [J]. Journal of Geriatric Cardiology, 2017, 14 (10) - 623
  • [2] Effectiveness and safety of glycoprotein IIb/IIIa inhibitors in patients with myocardial infarction undergoing primary percutaneous coronary intervention: A meta-analysis of observational studies
    Kouz, Remi
    Kouz, Simon
    Schampaert, Erick
    Rinfret, Stephane
    Tardif, Jean-Claude
    Nguyen, Michel
    Eisenberg, Mark
    Harvey, Richard
    Afilalo, Marc
    Lauzon, Claude
    Dery, Jean-Pierre
    Mansour, Samer
    Thao Huynh
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2011, 153 (03) : 249 - 255
  • [3] Meta-Analysis of Randomized Trials of Intracoronary Versus Intravenous Glycoprotein IIb/IIIa Inhibitors in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention
    Elbadawi, Ayman
    Elgendy, Islam Y.
    Megaly, Michael
    Ha, Le Dung
    Mahmoud, Karim
    Alotaki, Erfan
    Ogunbayo, Gbolahan O.
    Baig, Basarat
    Abuzaid, A. S.
    Saad, Marwan
    Depta, Jeremiah P.
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2017, 120 (07): : 1055 - 1061
  • [4] Practicability of Bivalirudin plus Glycoprotein IIb/IIIa Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis
    Li, Senjie
    Lv, Dongqing
    Liu, Caihong
    Jia, Yongping
    [J]. CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2021, 27
  • [5] Intracoronary versus intravenous glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in patients with STEMI: a systematic review and meta-analysis
    Hahn, JongSung
    Jeon, Jinyoung
    Geum, Min Jung
    Lee, Hyun Woo
    Shin, Jaekyu
    Chung, Woo-Young
    Yu, Yun Mi
    Ah, Young-Mi
    [J]. THROMBOSIS JOURNAL, 2023, 21 (01)
  • [6] Intracoronary versus intravenous glycoprotein IIb/IIIa inhibitors during primary percutaneous coronary intervention in patients with STEMI: a systematic review and meta-analysis
    JongSung Hahn
    Jinyoung Jeon
    Min Jung Geum
    Hyun Woo Lee
    Jaekyu Shin
    Woo-Young Chung
    Yun Mi Yu
    Young-Mi Ah
    [J]. Thrombosis Journal, 21
  • [7] Appropriate bolus administration of glycoprotein IIb/IIIa inhibitors for patients with acute coronary syndromes undergoing percutaneous coronary intervention: intracoronary or intravenous? A comprehensive and updated meta-analysis and systematic review
    Ali-Hassan-Sayegh, Sadegh
    Mirhosseini, Seyed Jalil
    Shahidzadeh, Arezoo
    Rahimizadeh, Elham
    Sarrafan-Chaharsoughi, Zahra
    Ghodratipour, Zahra
    Lotfaliani, Mohammad
    Rezaeisadrabadi, Mohammad
    Dehghan, Hamid Reza
    Bireta, Christian
    Weymann, Alexander
    Sabashnikov, Anton
    Popov, Aron-Frederik
    [J]. KARDIOLOGIA POLSKA, 2016, 74 (02) : 104 - 118
  • [8] Glycoprotein IIb/IIIa inhibitors and bivalirudin in patients undergoing percutaneous coronary intervention
    Mahmoudi, M.
    Waksman, R.
    [J]. MINERVA CARDIOANGIOLOGICA, 2012, 60 (01): : 95 - 100
  • [9] Intralesional versus intracoronary administration of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention in patients with acute coronary syndromes A meta-analysis of randomized controlled trials
    Sun, Binjie
    Liu, Zhen
    Yin, Hongshan
    Wang, Tao
    Chen, Tao
    Yang, Sen
    Jiang, Zhian
    [J]. MEDICINE, 2017, 96 (40)
  • [10] Meta-analysis of glycoprotein IIb/IIIa inhibition in primary percutaneous coronary intervention among unselected patients
    Kouz, R.
    Kouz, S.
    Schampaert, E.
    Rinfret, S.
    Eisenberg, M.
    Lauzon, C.
    Nguyen, M.
    Harvey, R.
    Huynh, T.
    [J]. CANADIAN JOURNAL OF CARDIOLOGY, 2007, 23 : 58C - 58C